Richard Brudnick - Jan 19, 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role: Officer title: Chief Business Officer and Head of Corporate Strategy
Signature: /s/ Yalonda Howze, Attorney-in-Fact for Richard Brudnick
Stock symbol: CDAKQ
Transactions as of: Jan 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/21/2022, 03:06 PM
Next filing: Feb 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDAKQ	Stock Option (Right to Buy)	Award	$0	+41K		$0.00	41K	Jan 19, 2022	Common Stock	41K	$7.21	Direct	F1
transaction	CDAKQ	Restricted Stock Units	Award	$0	+8.4K		$0.00	8.4K	Jan 19, 2022	Common Stock	8.4K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Officer title: Chief Business Officer and Head of Corporate Strategy